JP7705353B2 - Ｃｄ３８抗体を使用する併用療法 - Google Patents

Ｃｄ３８抗体を使用する併用療法 Download PDF

Info

Publication number
JP7705353B2
JP7705353B2 JP2021573297A JP2021573297A JP7705353B2 JP 7705353 B2 JP7705353 B2 JP 7705353B2 JP 2021573297 A JP2021573297 A JP 2021573297A JP 2021573297 A JP2021573297 A JP 2021573297A JP 7705353 B2 JP7705353 B2 JP 7705353B2
Authority
JP
Japan
Prior art keywords
seq
antibody
administered
days
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021573297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537134A5 (https=
JP2022537134A (ja
JPWO2020250033A5 (https=
Inventor
パルンボ、アントニオ
アリクメッツ、クリスティーナ
バーグ、デボラ
フェディク、エリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2022537134A publication Critical patent/JP2022537134A/ja
Publication of JP2022537134A5 publication Critical patent/JP2022537134A5/ja
Publication of JPWO2020250033A5 publication Critical patent/JPWO2020250033A5/ja
Application granted granted Critical
Publication of JP7705353B2 publication Critical patent/JP7705353B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021573297A 2019-06-10 2020-06-09 Ｃｄ３８抗体を使用する併用療法 Active JP7705353B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962859631P 2019-06-10 2019-06-10
US62/859,631 2019-06-10
PCT/IB2020/000443 WO2020250033A1 (en) 2019-06-10 2020-06-09 Combination therapies using cd-38 antibodies

Publications (4)

Publication Number Publication Date
JP2022537134A JP2022537134A (ja) 2022-08-24
JP2022537134A5 JP2022537134A5 (https=) 2023-06-20
JPWO2020250033A5 JPWO2020250033A5 (https=) 2023-06-20
JP7705353B2 true JP7705353B2 (ja) 2025-07-09

Family

ID=71527822

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573297A Active JP7705353B2 (ja) 2019-06-10 2020-06-09 Ｃｄ３８抗体を使用する併用療法

Country Status (7)

Country Link
US (1) US20220241413A1 (https=)
EP (1) EP3980064A1 (https=)
JP (1) JP7705353B2 (https=)
CN (1) CN113993543B (https=)
AR (1) AR120054A1 (https=)
TW (1) TWI870415B (https=)
WO (1) WO2020250033A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025122791A1 (en) * 2023-12-06 2025-06-12 Sanofi-Aventis U.S. Llc Use of anti-cd38 antibody in the treatment of new diagnosed multiple myeloma

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018013917A1 (en) 2016-07-15 2018-01-18 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
WO2019089832A1 (en) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
IT1320715B1 (it) 2000-10-19 2003-12-10 Cselt Centro Studi Lab Telecom Modulo generatore di circuiti per la decodifica di codiciconvoluzionali, metodo per la generazione di tale tipo di circuito e
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
EP1411851B1 (en) 2001-08-03 2006-11-02 Tyco Healthcare Group LP Marker for use with a tissue marking apparatus
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP2567976B1 (en) 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
EP3569245A1 (en) 2006-09-26 2019-11-20 Genmab A/S Combination treatment of cd38-expressing tumors
WO2010008726A1 (en) 2008-06-16 2010-01-21 Immunogen Inc. Novel synergistic effects
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
SI2621531T1 (sl) 2010-09-27 2017-06-30 Morphosys Ag Anti-cd38 protitelo in lenalidomid ali bortezomib za zdravljenje multiplega mieloma in nhl
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
RU2015134423A (ru) * 2013-03-13 2017-04-26 Инфламматори Респонс Ресёрч, Инк. Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
MX386886B (es) 2014-09-09 2025-03-12 Janssen Biotech Inc Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias.
MA41555A (fr) 2015-02-17 2017-12-26 Millennium Pharm Inc Polythérapie pour le traitement du cancer
MX389805B (es) 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
US20170121417A1 (en) 2015-11-03 2017-05-04 Janssen Biotech, Inc. Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
DK3827845T3 (da) * 2015-11-03 2022-05-23 Janssen Biotech Inc Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
US20180117150A1 (en) * 2016-11-01 2018-05-03 Janssen Biotech, Inc. Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide
JP7516047B2 (ja) * 2016-11-23 2024-07-16 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤とｃｄ３８阻害剤とを含む医薬組み合わせ物及びその使用方法
US20200308296A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone
US20210171650A1 (en) * 2019-05-14 2021-06-10 Sanofi Methods of administering anti-cd38 antibody

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018013917A1 (en) 2016-07-15 2018-01-18 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
WO2019089832A1 (en) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Jeroen LAMMERTS VAN BUEREN et al.，"Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79"，Blood，2014年12月06日，Vol. 124, No. 21，p.3474-3474，DOI: 10.1182/blood.V124.21.3474.3474
Niels W. C. J. VAN DE DONK et al.，"Monoclonal antibodies targeting <scp>CD</scp>38 in hematological malignancies and beyond"，Immunological Reviews，2016年02月10日，Vol. 270、No. 1，p.95-112，DOI: 10.1111/imr.12389

Also Published As

Publication number Publication date
US20220241413A1 (en) 2022-08-04
CN113993543A (zh) 2022-01-28
JP2022537134A (ja) 2022-08-24
EP3980064A1 (en) 2022-04-13
TW202112373A (zh) 2021-04-01
AR120054A1 (es) 2022-02-02
CN113993543B (zh) 2024-07-12
TWI870415B (zh) 2025-01-21
WO2020250033A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
JP7526099B2 (ja) 抗ｃｄ３８抗体の皮下投薬
JP2024023247A (ja) 抗ｃｄ３８抗体の皮下投与
JP2022023051A (ja) 瘻孔を伴うクローン病の治療用ベドリズマブ
JP7164530B2 (ja) Ｉｌ－４ｒ阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
KR20230131464A (ko) 항-cd19 병용 요법
JP2017502923A (ja) 抗ｃｘｃｒ４抗体によるｃ１０１３ｇ／ｃｘｃｒ４関連ワルデンシュトレームマクログロブリン血症の治療
JP2023548064A (ja) 抗ｃｄ２０／抗ｃｄ３二重特異性抗体及び抗ｃｄ７９ｂ抗体薬物コンジュゲートによる処置のための投与
KR20200010472A (ko) 항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임
KR20250004508A (ko) 암의 치료를 위한 조합 요법
JP7705353B2 (ja) Ｃｄ３８抗体を使用する併用療法
IL292926A (en) Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists
AU2024311205A1 (en) Treatment method and use of pharmaceutical combination containing conjugate
JP7808102B2 (ja) モスネツズマブおよびポラツズマブベドチンを用いたｃｄ２０陽性増殖性障害の処置のための方法
JP2025522729A (ja) ガレクチン－９を阻害する抗体を用いた悪性血液疾患の処置
KR20240135663A (ko) 미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
JP2024517796A (ja) 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療
US20230090868A1 (en) Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma
RU2810953C2 (ru) Подкожное дозирование антител к cd38
WO2025085792A1 (en) Treatment of hematological malignancies with antibodies inhibiting galectin-9
RU2802812C2 (ru) Лечебный подход, предназначенный для лечения комбинацией антитела к CD19 и венетоклакса
CN121127494A (zh) 用于治疗自身免疫性疾病的抗cd38抗体
JP2024516019A (ja) 抗ｂａｆｆｒ抗体を使用する全身性エリテマトーデスのための治療
WO2025188583A1 (en) Combination therapies for the treatment of hr+/her2- metastatic or locally advanced breast cancer
CA3221834A1 (en) Combination therapies for the treatment of non-small cell lung cancer
EP4583913A1 (en) Subcutaneous dosing of anti-cd38 antibodies for treating patients with moderate to severe systemic lupus erythematosus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240917

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250603

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250627

R150 Certificate of patent or registration of utility model

Ref document number: 7705353

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150